News Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
5.14 ^USD	+3.01%		-7.55%	-34.02%

Apr. 09	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT
Apr. 09	Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 09	MT
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	Apr. 09	MT
Syros Gets FDA Fast-Track Designation for Tamibarotene	Apr. 09	DJ
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	Apr. 09	BU
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	Apr. 09	CI
Syros Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Apr. 03	AQ
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 02	BU
Health Care Rises as Upward Momentum Builds -- Health Care Roundup	Mar. 28	DJ
Health Care Jumps as Upward Momentum Builds -- Health Care Roundup	Mar. 27	DJ
Transcript : Syros Pharmaceuticals, Inc., 2023 Earnings Call, Mar 27, 2024	Mar. 27
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q4 Revenue $387,000	Mar. 27	MT
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	Mar. 27	BU
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene	Mar. 25	MT
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial	Mar. 25	BU
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial	Mar. 25	CI
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024	Mar. 20	BU
Syros to Participate in TD Cowen 44th Annual Health Care Conference	Feb. 27	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Summary

Filters